At the news
? NEUTRALIMPACT 2/10 PRESS-RELEASE filed May 22, 2026 at 17:15 ET
Iovance Biotherapeutics granted inducement stock options covering 93,340 shares to 13 new non-executive employees under its 2021 Inducement Plan. The options have an exercise price of $3.70 and vest over three years. This is a routine equity grant for new hires, not a material financial event.
- 93,340 shares of common stock granted as inducement stock options to 13 new non-executive employees.
- Exercise price of $3.70, equal to the closing price on the grant date (May 21, 2026).
- Options vest over three years: one-third on first anniversary, remainder in quarterly installments.
- Granted under the Amended and Restated 2021 Inducement Plan per Nasdaq Listing Rule 5635(c)(4).
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access